Company: DelMar Pharmaceuticals, Inc
Symbol: NASDAQ: DMPI
Length: 00:26:11
Presenter: Jeffrey Bacha, Chairman
Occasion: Richmond Club Lunch, Toronto

DelMar Pharmaceuticals, Inc. was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.

Product Information
The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
For more information please visit: www.delmarpharma.com
Head Office:
Suite 720 – 999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
Telephone: +1 604 629 5989
E: info@delmarpharma.com
W: www.delmarpharma.com

Leave a Comment

Your email address will not be published. Required fields are marked *

Get Access to The Richmond Clubs Latest Stock Picks For FREE!

 

Don’t miss your chance to get in on the top stocks we think are the best buys now inside our exclusive Richmond Club Stock Advisor Letter.

Led by Chartered Investment Manager, Greg Beckett, the average stock pick inside The Richmond Club is up 1,301% vs. just 153% for the S&P.

This is your opportunity to become part of an exclusive membership led by the Richmond Club that has seen an average of 16.45 % gains over the past 15 years!

If you want to take advantage of this buying opportunity, simply enter your email address below to access our secure sign-up page.

Join The Richmond Advisor Free For 2-Months

By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy